Effect of penbutolol on neuroendocrine responses to buspirone and mood in SSRI-refractory patients: a preliminary study
✍ Scribed by E. M. Clifford; R. Whale; T. Sharp; P. J. Cohen
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 158 KB
- Volume
- 14
- Category
- Article
- ISSN
- 0885-6222
No coin nor oath required. For personal study only.
✦ Synopsis
The b-adrenoceptor antagonist, penbutolol, is an eective serotonin 1A (5-HT 1A ) receptor antagonist in the rat and through this action enhances the ability of selective serotonin re-uptake inhibitors (SSRIs) to increase levels of serotonin in terminal ®elds. In healthy volunteers, penbutolol (40 mg orally), produced a modest attenuation of the prolactin response to the 5-HT 1A receptor antagonist, buspirone (30 mg orally), but did not antagonise the hypothermic response. Furthermore, penbutolol addition (40 mg daily for 3 weeks) failed to improve the symptomatology of 10 depressed patients who had shown an inadequate clinical response to serotonergic antidepressants. These preliminary data suggest that at the typical dose used to treat hypertension, penbutolol does not antagonise 5-HT 1A autoreceptors in humans and does not augment the eect of serotonergic antidepressants in treatment non-responders.